Anti-CD70 antibody drug conjugates
Inventors
Barnett, Richard S • KNUDSEN, Nickolas • Sun, Ying • Biroc, Sandra • Buss, Timothy • Javahishvili, Tsotne • Bresson, Damien • Srinagesh, Shailaja • HEWET, Amha • PINKSTAFF, Jason
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Abstract
This invention relates to anti-CD70 antibodies and antibody drug conjugates comprising at least one non-naturally-encoded amino acid. Disclosed herein are αCD70 antibodies with one or more non-naturally encoded amino acids and further disclosed are antibody drug conjugates wherein the αCD70 antibodies of the invention are conjugated to one or more toxins. Further disclosed are methods for using such non-natural amino acid antibody drug conjugates, including therapeutic, diagnostic, and other biotechnology uses.
Core Innovation
The invention provides anti-CD70 antibody conjugates in which the antibody is conjugated to a dolastatin via a non-natural amino acid in the anti-CD70 antibody. The resulting compound is defined by Formula (VIII) or Formula (IX), including optional structural elements A and B, a dolastatin-related Z region, and a linker L selected from specified linker classes. The structural definitions use broad variable ranges for the conjugate scaffold and related substituents.
The disclosure further describes non-natural amino acids bearing aromatic amine sidechains and masked or protected aromatic amine groups for site-specific conjugation, together with aldehyde-containing dolastatin linker derivatives that participate in conjugation chemistry to form oxime-linked and alkylated aromatic-amine dolastatin linker derivatives. It also describes electrophilic carbonyl/dicarbonyl and ketoalkyne-type functional amino acids as reactive handles, with optional masked or protected forms, and states that these non-natural amino acids can be incorporated into polypeptides and polynucleotides.
Formula (VIII) or (IX) further defines R1 as a polypeptide comprising a heavy chain variable region having the amino acid sequence of SEQ ID NO: 1, and R2 as a polypeptide. The Z region is defined with R5, R6, R7, R8, and Ar, including phenyl or pyridine aromatic options, and the linker L includes repeating -(alkylene-O)n-alkylene motifs and related linker structures with W and U substructures. The disclosure also extends to active metabolites and pharmaceutically acceptable prodrugs or solvates, and includes pharmaceutical compositions containing the compound with a pharmaceutically acceptable carrier, excipient, or binder.
Claims Coverage
The consolidated claim coverage centers on one independent anti-CD70 antibody-dolastatin conjugate claim defined by Formula (VIII) or (IX), with conjugation via a non-natural amino acid and extensive structural definition of A, B, Z, and L. A further independent scope is directed to a pharmaceutical composition containing the defined compound with a pharmaceutically acceptable carrier, excipient, or binder. Across the input items, the inventive features repeatedly emphasize the antibody heavy chain variable region sequence, the dolastatin-related substitution pattern, and the selected linker architectures.
Anti-CD70 antibody conjugated to dolastatin via a non-natural amino acid
A compound comprising Formula (VIII) or (IX), wherein the compound is an anti-CD70 antibody conjugated to a dolastatin, and wherein the conjugation occurs via a non-natural amino acid in the anti-CD70 antibody.
Formula (VIII) or (IX) structural definition with optional A and B
Formula (VIII) or (IX) defines optional A and B elements selected from broad linker and linkage classes, including lower alkylene, substituted lower alkylene, lower cycloalkylene, lower alkenylene, alkynylene, lower heteroalkylene, lower heterocycloalkylene, arylene, heteroarylene, alkarylene, aralkylene, and heteroatom-containing linker motifs.
Antibody polypeptide variables including SEQ ID NO: 1
R1 is a polypeptide comprising a heavy chain variable region having the amino acid sequence of SEQ ID NO: 1, and R2 is a polypeptide.
Dolastatin-related Z substitution pattern
Z is defined with R5 being H, COR8, C1-C6 alkyl, or thiazole; R8 being OH; R6 being OH or H; Ar being phenyl or pyridine; and R7 being H or C1-C6 alkyl.
Linker L selected from specified alkylene-based motifs
L is selected from linker classes including alkylene-based motifs, repeating -(alkylene-O)n-alkylene motifs, and related linker segments incorporating W and U substructures, with repeat indices n and related indices independently an integer greater than or equal to one.
Pharmaceutical composition with pharmaceutically acceptable carrier, excipient, or binder
A pharmaceutical composition comprising the compound together with a pharmaceutically acceptable carrier, excipient, or binder.
The consolidated claim scope is an anti-CD70 antibody-dolastatin conjugate defined by Formula (VIII) or (IX), mediated by a non-natural amino acid and constrained by defined linker and substituent architecture. The recurring inventive points are the antibody sequence requirement, the dolastatin-related Z definition, the selectable linker L motifs, and the pharmaceutical composition embodiment.
Stated Advantages
The described non-natural amino acids provide reactive handles for site-specific conjugation.
Masked or protected forms are used for conjugation to an appropriate partner.
The described functional groups and linkers are suitable for downstream derivatization and conjugation.
Targeted depletion/inhibition of CD70-expressing cells beyond CD70/CD27 blocking.
Stability in aqueous solution under mildly acidic pH.
Documented Applications
Anti-CD70 antibody conjugate construction via the non-natural amino acid.
Chemical structures for exemplary anti-CD70/dolastatin ADC conjugates linked by a non-natural amino-acid conjugation motif.
In vivo and in vitro efficacy/clinical evaluation of CD70-ADC constructs in renal cell carcinoma and Burkitt lymphoma models.
Cytotoxicity studies, including Caki-1 cytotoxicity and IC50 readouts.
Phase I/II clinical trial evaluation using RECIST criteria.
Therapeutic uses of the anti-CD70 antibody drug conjugates.
Diagnostic uses of the anti-CD70 antibody drug conjugates.
Anti-CD70 antibody drug conjugates using dolastatin linker derivatives/constructs.
Embodiments where drug/linker portions correspond to dexamethasone, dasatinib, FK506 and derivatives.
Interested in licensing this patent?